NACAD

Across TCGA pan-cancer cohorts, NACAD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NACAD data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NACAD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NACAD expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where NACAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.859	0.616	<.001	51	view →
UCEC	OS	Median	II,III,IV	0.453	1.000	.003	32	view →
PDAC	DFS	Median	II,III,IV	0.193	0.479	.004	11	view →
LSCC	OS	Tertile	III,IV	0.508	0.979	.013	9	view →
CCRCC	OS	Quartile	All	0.554	1.000	.037	5	view →
GBM	OS	Median	All	0.747	0.883	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NACAD–HNSC (DFS)

Open the HNSC breakdown →